Prosecution Insights
Prosecution Insights
Technology area: Biotechnology & Pharmaceuticals
2 pending office actions • 2 art units • 2 examiners • 0 of 2 (0%) have an AI response strategy ready
Professional Compounding Centers Of America Inc. currently has 2 pending office actions in the Biotechnology & Pharmaceuticals technology area. These actions are handled by 2 distinct examiners across 2 distinct art units. KIM, DANIELLE A is the busiest examiner for the portfolio, with 1 busiest examiner pending matter under review. The presence of 2 pending office actions in 2 distinct art units indicates that the company's research and development efforts span different regulatory categories within the pharmaceutical sector.
With 2 distinct examiners involved, the prosecution strategy must account for the specific preferences of each individual. KIM, DANIELLE A manages 1 busiest examiner pending case, while the other pending action is handled by a different examiner in a separate art unit. This distribution across 2 distinct art units suggests a diverse technical portfolio that requires specialized knowledge for each of the 2 pending office actions. Practitioners must coordinate their responses to ensure that the 1 busiest examiner pending matter and the other active case remain consistent with the company's overall intellectual property goals.
Based on the USPTO statutory response window for each pending office action. 1 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §103 only | 1 (50%) |
| Multi-statute (no §101) | 1 (50%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| KIM, DANIELLE A | 1 | 37.1% | +56.3% |
| KAMM, JUDITH MARIE | 1 | 43.5% | +56.6% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 16883625 | SKIN PERMEATION ENHANCING COMPOSITION | KAMM, JUDITH MARIE | 29d overdue |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 2 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 16883625 | SKIN PERMEATION ENHANCING COMPOSITION | KAMM, JUDITH MARIE | 29d overdue |
| 18485090 | ANHYDROUS ORAL PHARMACEUTICAL SUSPENSIONS | KIM, DANIELLE A | — |
| Art Unit | Apps |
|---|---|
| 1613 | 1 |
| 1611 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18485090 | ANHYDROUS ORAL PHARMACEUTICAL SUSPENSIONS | KIM, DANIELLE A | 1613 | §103 | Non-Final OA | — | Pending | Oct 11, 2023 |
| 16883625 | SKIN PERMEATION ENHANCING COMPOSITION | KAMM, JUDITH MARIE | 1611 | §103§112 | Non-Final OA | 29d overdue | Pending | May 26, 2020 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free Trial